Hidrocortisona Ursapharm (Hydrocortisone Acetate)

Hidrocortisona Ursapharm is used for short‑term control of ocular inflammation when a topical corticosteroid is appropriate.

• Management of postoperative inflammation following cataract or intraocular surgery.
• Treatment of acute allergic conjunctivitis with significant redness and itching.
• Control of anterior uveitis or iritis to reduce intra‑ocular swelling.
• Reduction of inflammatory keratitis where steroid therapy is indicated.
• Relief of ocular inflammation after traumatic injury to the eye.
• Adjunct therapy for severe dry‑eye disease with inflammatory component.
• The medication is applied directly to the affected eye as directed by a healthcare professional.

• Hydrocortisone acetate is a glucocorticoid pro‑drug that, after ocular absorption, is hydrolyzed to active hydrocortisone. The active molecule binds intracellular glucocorticoid receptors in ocular tissues, forming a receptor‑ligand complex that translocates to the nucleus and modulates gene transcription. This interaction suppresses the synthesis of pro‑inflammatory cytokines, prostaglandins, and leukotrienes, thereby decreasing vascular permeability, leukocyte infiltration, and edema within the eye.

Topical ocular use of hydrocortisone acetate may be associated with local and, rarely, systemic adverse reactions.

Common

• Transient burning or stinging sensation upon instillation.
• Temporary blurred vision that resolves after a few minutes.
• Mild increase in intra‑ocular pressure with prolonged use.
• Development of posterior subcapsular cataract after long‑term therapy.
• Conjunctival hyperemia or mild irritation.
• Mild dry eye sensation or tearing.

Serious

• Secondary ocular infection such as bacterial or fungal keratitis.
• Glaucoma or rapid rise in intra‑ocular pressure requiring treatment.
• Severe cataract formation affecting visual acuity.
• Delayed corneal wound healing after surgery or trauma.
• Allergic or hypersensitivity reaction presenting with swelling and redness.

When using Hidrocortisona Ursapharm, clinicians and patients should observe several precautions to minimize risks and ensure safe therapy.

• Assess intra‑ocular pressure before initiating therapy and monitor periodically during treatment.
• Avoid use in eyes with active viral, fungal, or bacterial infections unless directed by a specialist.
• Limit duration of therapy to the shortest effective period to reduce cataract and glaucoma risk.
• Do not use in patients with known hypersensitivity to hydrocortisone acetate or other corticosteroids.
• Exercise caution in patients with diabetes, as systemic absorption may affect glucose control.
• Inform patients to report persistent eye pain, vision changes, or signs of infection promptly.

Hydrocortisone acetate eye drops can interact with other ophthalmic or systemic agents; awareness of these interactions helps prevent reduced efficacy or increased toxicity.

Avoid

• Concurrent use with potent topical ocular NSAIDs, which may increase risk of corneal ulceration.
• Co‑administration with other corticosteroid eye preparations, leading to additive intra‑ocular pressure elevation.
• Use with antiviral eye drops for herpetic keratitis without specialist guidance, as steroids may exacerbate infection.

Use with caution

• Systemic corticosteroids, which can potentiate systemic effects from ocular absorption.
• Beta‑blocker eye drops, as combined therapy may affect intra‑ocular pressure control.
• Anticholinergic eye drops, which may influence tear film stability when combined with steroids.